AllianceBernstein’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

AllianceBernstein’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-23,400	Closed	-$540K	–	3364
2020 Q4	$540K	Hold	23,400	–	–	﹤0.01%	2555
2020 Q3	$238K	Sell	23,400 -900	-4%	-$12.1K	﹤0.01%	2910
2020 Q2	$362K	Buy	24,300 +12,200	+101%	+$188K	﹤0.01%	2803
2020 Q1	$147K	Buy	+12,100	New	+$193K	﹤0.01%	2879

AllianceBernstein's PRVL Position: Q1 2021 in Review

AllianceBernstein sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 23,400 shares — an estimated $540K sold.

AllianceBernstein first reported a position in PRVL in Q1 2020 and held it in 4 quarters. The position peaked at $540K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

AllianceBernstein reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
AllianceBernstein sold 23,400 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $540K.
AllianceBernstein first reported a position in Prevail Therapeutics Inc. Common Stock in Q1 2020 and held it in 4 quarters.
AllianceBernstein's Prevail Therapeutics Inc. Common Stock position peaked at $540K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on AllianceBernstein's 13F filing for Q1 2021, filed 6 May 2021.